These studies report that ADAM17 gene expression is significantly enhanced in both early and advanced ovarian cancer compared with that in normal ovaries [34] and that higher ADAM17 expression is associated with significantly decreased PFS of grade 1 and 2 serous ovarian cancer patients [36]. Here, ADAM17 is linked to ovarian carcinoma.